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Abstract 
 
Background 
Chemotherapy-induced premature ovarian insufficiency (POI) impacts fertility and other 
aspects of women’s health. The OPTION trial tested whether administration of a 
gonadotropin hormone releasing hormone (GnRH) agonist during chemotherapy for early 
breast cancer reduced the risk of POI. 
 
Patients and Methods 
This was a prospective, randomized, parallel group study of the GnRH agonist goserelin 
administered before and during chemotherapy for breast cancer  with stage I-IIIB disease. The 
primary outcome was amenorrhoea between 12 and 24 months after randomization, 
supported by elevated follicle stimulating hormone (FSH) concentrations to give an additional 
analysis as rate of POI. 
 
Results 
A total of 227 patients were randomized and the primary analysis was conducted on 202 
patients. Goserelin reduced the prevalence of amenorrhoea between 12 and 24 months to 
22% vs 38% in the control group (P=0.015) and the prevalence of POI to 18.5% vs 34.8% in 
the control group (P=0.048). FSH concentrations were also lower in all women treated with 
goserelin at both 12 and 24 months (P = 0.027, P = 0.001 respectively). The effect of 
goserelin was not statistically significant in women >40 years. Assessment of the ovarian 
reserve using anti-Müllerian hormone (AMH) showed a marked fall in both groups during 
treatment to median values of 5% of pretreatment levels in the control group and 7% in the 
goserelin group, which were not significantly different between groups.  
 
Conclusion 
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This study shows that goserelin reduced the risk of POI in women treated with chemotherapy 
for early breast cancer, with particular efficacy in women aged ≤40 years old.  The degree of 
ovarian protection also seems limited and the clinical significance for fertility and longer-term 
prevention of estrogen deficiency-related outcomes needs to be determined.   
Key words: breast cancer  , ovary  , GnRH analogue  , chemoprotection 
 
Trial registration: EudraCT 2004-000133-11 
 
Key message 
This RCT of GnRH agonist administration during chemotherapy for early breast cancer for 
ovarian protection showed a benefit in women aged under 40 years, but with no detected 
benefit in older women.  The use of a biomarker of the ovarian reserve indicated that the 
amount of ovarian function preserved by this approach may be small. 
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Introduction 
 
The improved survival of women with early breast cancer in recent years [1] has led to an 
increased interest in the long term consequences of treatment. Amongst these, ovarian 
toxicity from chemotherapy is important in younger women, as it may result in loss of fertility 
and early menopause (premature ovarian insufficiency, POI) with consequent increased risk 
of a range of adverse health effects including menopausal symptoms, osteoporosis, sexual 
dysfunction, cardiovascular disease and loss of neurological function [2]. 
A number of observational studies have suggested a benefit from GnRH agonist suppression 
of ovarian function, but the data from randomized controlled trials (RCTs) remain mixed [3-
7]. The most recent substantial RCT in women with breast cancer [8] found evidence of 
reduced risk of ovarian failure with goserelin treatment during chemotherapy, and meta-
analyses also report varying results [9, 10]. Trials in women with Hodgkin lymphoma also 
report varying results [11, 12]. 
 
Recall of menses may be unreliable unless based on a daily diary, and while amenorrhoea is 
clear, infrequent or irregular menses may indicate incipient POI. This trial was set up to 
establish whether the use of goserelin in women who require chemotherapy for operable 
hormone-insensitive breast cancer or for whom ovarian suppression is not considered a 
necessary part of treatment, may reduce the risk of POI. This primary outcome was the 
prevalence of amenorrhoea at 12-24 months, secondarily combined with elevated follicle-
stimulation hormone [FSH] concentration giving the prevalence of POI.  
Anti-Müllerian hormone (AMH) is also a valid and valuable marker of ovarian follicle reserve 
[13].  Pre-treatment AMH has been suggested to predict long term ovarian function following 
chemotherapy for early breast cancer, and post-treatment concentrations are an indicator of 
the remaining ovarian reserve in women who maintain menstrual function, thus providing a 
quantitative estimate of the degree of ovarian protection [14, 15]. 
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Patients and Methods 
Premenopausal patients with histologically confirmed breast cancer who were to receive 
adjuvant or neo-adjuvant chemotherapy were eligible for ‘OPTION’. All patients gave informed 
consent and the study received Ethical Committee approval (South West Multi-centre Research 
Ethics Committee, ref MREC/03/6/90).  The original protocol restricted the entry of patients to 
those with ER-negative tumors only, but patients with ER-positive tumors for whom the 
investigator did not deem ovarian suppression necessary as part of the treatment were 
subsequently allowed entry to the trial after a protocol amendment. The breast cancers could 
be up to stage IIIB (T1-T4 with N0-2) and complete excision of the tumor before adjuvant 
chemotherapy or planned after neoadjuvant therapy was required. The patients had to be 
pre-menopausal (defined as regular menses in the 12 months prior to chemotherapy). 
Metastatic disease was an exclusion criterion. Patients who had had prior chemotherapy or 
endocrine therapy were ineligible. Chemotherapy regimens included 6-8 cycles of 
cyclophosphamide and/or anthracycline-containing regimens with or without a taxane. 
Patients were randomized to receive a 3.6mg goserelin implant or nothing starting at least 
one week, and preferably two weeks, prior to the start of the chemotherapy treatment, and 
continuing goserelin 3-4 weekly until the end of the chemotherapy treatment. Chemotherapy 
had to start within 8 weeks of definitive surgery. Radiotherapy was as per standard protocol 
for each centre. 
 
Randomization was centrally performed by telephone to the trial center, eligibility was 
confirmed verbally, and treatment was allocated by computer-generated lists. Pre-treatment 
evaluation included history and physical examination, haematology and biochemistry profiles, 
chest x-ray, electrocardiograph, and measurements of estradiol, FSH, and luteinizing 
hormone (LH) which were performed locally; serum was also stored for later measurement of 
AMH which was performed centrally using the Roche Elecsys automated assay. 
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Patients were followed-up 6-monthly for 2 years and then 12-monthly for a further 3 years. 
Hormone levels were checked at cycle 3, after the final cycle, then at 9 months, 12 months, 
then annually. A menstruation diary was kept for 24 months from the start of chemotherapy. 
 
Statistical analysis 
The primary outcome was the rate of amenorrhea ie no menses between 12 and 24 months 
after randomization, also combined with elevated FSH concentrations to give rate of POI. For 
the sample size calculation, it was assumed that the rate of amenorrhea would be 40% in the 
40 years and under age-group and 80% in the over 40 age-group. At the time of conception 
of the trial, two uncontrolled studies had suggested that goserelin might reduce the rate of 
premature menopause to 20%. A one-sided test with 5% false-positive rate was used to 
calculate the sample size to give an 80% chance of detecting an absolute reduction from 
40% to 20% in the 40 years and under group and from 80% to 55% in the older age group. It 
was intended to recruit a total of 250 patients and allowing for a 15% loss to follow-up. 
Randomization was stratified by age (aged 40 years or younger and those over 40 years) 
and by center. 
 
Analysis of binary endpoints was conducted using a two-sided Fisher’s Exact test. 
Comparisons of the hormone concentrations between treatment groups were by the Mann-
Whitney test. An exploratory logistic regression analysis was performed to assess the 
predictive value of age, total cyclophosphamide dose and baseline AMH for amenorrhoea. To 
ensure an intention to treat analysis where the primary end-point data were unobtainable, two 
alternative imputations were made: 
1. Best case: All patients with missing information were assumed not to have experienced 
amenorrhea (regardless of treatment arm). 
2. Worst case: All patients with missing information were assumed to have experienced 
amenorrhea (regardless of treatment arm). 
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Results 
 
227 patients were randomized between 26 August 2004 and the end of December 2009.  Of 
these, 3 in each arm were omitted from this analysis because they had died within 24 months 
of randomization and had therefore unknown menstrual status at 24 months. The age 
distribution, chemotherapy regimens and ER status for these 221 patients are described in 
Table 1, and did not differ between the 2 groups. For a further 19 patients (11 in the control 
arm and 8 in the intervention arm), menstrual status during the interval between the 12 
month follow up visit and the 24 month follow up visit could not be determined from the data 
available.  The primary analysis was therefore conducted on 202 patients (figure 1).   
 
Primary outcome 
The prevalence of amenorrhoea during chemotherapy was, as expected, much higher in the 
goserelin group (97.9% vs 63.5%, P<0.0001). By 12 months menses had resumed in many 
women, in both groups.  
 
The main outcome of this trial showed a difference in the prevalence of amenorrhoea 
between 12 and 24 months, being 22% in the goserelin group vs 38% in the control group 
(P=0.015, table 2). After imputing missing data both as worst case (all with amenorrhoea) or 
best case (none with amenorrhoea) scenarios, there remained significant differences 
between groups, with reduced prevalence of amenorrhoea in the goserelin group (table 2). 
This apparent protective effect of goserelin was further assessed using the definition of POI 
ie amenorrhoea with elevated FSH concentrations using a FSH cutoff of 25IU/L [16]. The 
prevalence of POI in the goserelin group was 18.5% vs 34.8% in the control group (P=0.048), 
thus closely mirroring the amenorrhoea results. 
 
Given the likely importance of age in determining risk of chemotherapy-related amenorrhoea, 
groups were stratified by age, using a cutoff of 40 years. This analysis showed a protective 
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effect of goserelin on both the prevalence of amenorrhoea alone and on POI (amenorrhoea 
plus high FSH) in women aged ≤40 (amenorrhoea: 10.0% vs 25.4%, P = 0.032; POI: 2.6% vs 
20.0%, P=0.038). The effect was less clear and not statistically significant in women >40 
years (amenorrhoea: 42.9% vs 54.2%, P = 0.376; POI: 42.3% vs 47.2%, p=0.798). 
 
Nine pregnancies occurred in women in the goserelin group (including 2 pregnancies each 
for 2 women) and 6 in the control group (including 2 pregnancies in one woman). A total of 
24 deaths occurred, 9 in the goserelin group and 15 in the control group. 
 
Hormonal evaluations 
The control group showed a fall in estradiol concentrations during and following 
chemotherapy, with resultant rises in FSH and LH (figure 2).  The goserelin group showed 
the expected significant reductions in LH, FSH and E2 during treatment (figure 2), with the 
estradiol changes also reflecting the effect of chemotherapy. Consistent with the reduced 
prevalence of POI in the treated group, FSH concentrations were lower than in the control 
group at both 12 and 24 months (P = 0.027, P = 0.001 respectively). 
There was a marked fall in AMH in both groups during treatment to median values of 
approximately 5% of pretreatment levels in the control group and to 7% in the goserelin 
group (figure 2), changes that were not significantly different between groups.  
 
Logistic regression analysis was performed to assess the predictive value of factors 
associated with amenorrhoea (supplementary table 1).  Pretreatment AMH was shown to be 
a predictor of post-treatment amenorrhoea (odds ratio 0.43, 95% confidence interval [CI] 
0.23-0.80, P=0.01), as was age (OR 1.28, CI 1.18-1.39, P<0.001), although after adjustment 
for age, the effect of pretreatment AMH was no longer significant. Total cyclophosphamide 
dose was not predictive (OR 1.15, CI 0.99-1.34, P = 0.07). 
 
Discussion 
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Our results demonstrate that the use of the GnRH analogue goserelin provides some 
protection of ovarian function during chemotherapy for early breast cancer. The effect 
appears age-dependent, being less clear for women who are older than 40. It may be that 
the relative sample sizes in the two age cohorts accounts for some of this difference, 
accentuated by the slight randomization imbalance in the older age group. Results of AMH 
analysis, albeit only in a subgroup, demonstrated a very marked fall in this marker of the 
ovarian reserve in all women, and thus any protection of ovarian reserve is likely to be small. 
 
There remains uncertainty concerning the efficacy or otherwise of trying to protect ovarian 
function from chemotherapy with GnRH-agonist mediated gonadotrophin suppression [17].  
The present data are comparable with the results of some but not all RCTs of GnRH 
analogue treatment for the prevention of ovarian toxicity from chemotherapy. Two recent 
meta-analyses came to different conclusions: one, of 12 RCTs including 1231 breast cancer 
patients indicated that GnRH analogue treatment reduced the risk of POI (OR 0.36, 95% CI 
0.23-0.57) although significant heterogeneity between study results was identified [10]. The 
second, of 10 trials including 907 women, concluded that GnRH analogues did not increase 
the proportion of women with ovarian function after chemotherapy with a risk ratio of 1.12, 
95% CI 0.99-1.27 [9]. Additionally, GnRH analogue use in women receiving chemotherapy 
for lymphoma show inconsistent results [11, 12].  The use of GnRH analogues to protect 
ovarian function has however been endorsed by the 2015 St Gallen International Consensus 
Panel [18] and for women with hormone receptor negative breast cancer in the guidelines 
of the National Comprehensive Cancer Network. This study provides substantial additional 
confidence in this effect, being the second largest trial reported, but suggests that any 
benefits are largely confined to women aged <40 years. 
 
The mechanism whereby GnRH analogues might provide ovarian protection is unclear.. Loss 
of growing follicles due to the effects of chemotherapy may additionally remove local 
inhibitory influences on the activation of growth of primordial follicles, thus accelerating 
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depletion of the ovarian reserve [19]. There are also both mouse and non-human primate 
experimental data indicating a protective effect of GnRH analogues [20, 21] . 
 
In this and previous similar trials the primary outcome measure has been ovarian function as 
revealed by amenorrhoea or POI. These measures do not assess loss of the follicle pool 
within the ovary. AMH is a marker of the number of small growing follicles in the ovary, and 
indirectly reflects the number of primordial follicles (the ‘ovarian reserve’) [13]. In women with 
breast cancer, pretreatment AMH (with age) predicts remaining ovarian function after 
chemotherapy [15]. Post-treatment AMH indicates the degree of loss of ovarian reserve [14, 
22] as women who retain ovarian function after chemotherapy are still likely to experience an 
early menopause [23]. Analysis of AMH post chemotherapy may be of value in predicting 
remaining reproductive lifespan.  The degree of fall in AMH shown here highlights the 
magnitude of the ovarian damage even in those without POI, with AMH at 2 years being 
reduced by 95% in the control group and by 97% in the goserelin group, although sample 
collection was incomplete. Thus the amount of 'saved' ovarian function is modest, but may 
be of clinical consequence particularly in younger women where it might allow an increased 
opportunity for fertility. Longer-term benefits from any reduction in the consequences of 
estrogen deficiency have yet to be investigated. 
 
Age and AMH were predictive of amenorrhea, the latter not being significant when adjusted 
for age. This is consistent with previous analyses of AMH as a predictor of post-chemotherapy 
ovarian function [15], and the importance of age in that context [24, 25]. This supports the 
concept that the size of an individual woman’s ovarian reserve as well as her age determines 
her risk of POI following chemotherapy. 
 
Additional data from a bone sub-study of this trial also suggested that goserelin provides 
some degree of ovarian protection from chemotherapy. Although the addition of goserelin to 
chemotherapy increased bone turnover during treatment, the return of bone biomarkers to 
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the normal range after cessation of treatment was more frequent with goserelin and 
suggested that it may offer sufficient ovarian protection against chemotherapy-induced POI 
to negate the long term altered bone turnover associated with POI [26].  
 
Although the number of recurrences in our study are too few for meaningful comparison, the 
results of other trials that included mostly hormone-receptor positive breast cancer have 
been encouraging in respect of safety and efficacy [10], an important observation given the 
apparent survival benefit associated with chemotherapy-induced amenorrhoea in women 
with estrogen receptor positive breast cancer [27]. 
 
We conclude that the impact of using a GnRH analogue moderately reduces the risk of POI 
induced by standard adjuvant chemotherapy for early breast cancer in young women, but 
that this effect is uncertain for women over 40 years old. 
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Figures legends 
 
Figure 1. Consort diagram showing disposition of patients recruited. 
 
Figure 2. Hormonal evaluation.   Blue, Control group; red, Goserelin group, data are shown 
as mean± sem. Note that AMH is shown on a log10 scale to allow the very low 
concentrations during and post chemotherapy to be more clearly shown. EoT: end of 
chemotherapy treatment. * P = 0.027, P = 0.001 vs control group at 12 and 24 months 
respectively. Sample size for Control group 59-107 for FSH, LH, E2 and 37-56 for AMH; for 
Goserelin group, 63-96 and 36-53 respectively. 
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Table 1. Demographics of patients recruited to the study. 
 
    
Chemotherapy 
alone 
Chemotherapy 
plus Goserelin 
  N 118 103 
Age at randomisation 
(years) 
      
  N 118 103 
  Median 38.8 37.9 
  (Range) (24.8, 51.1) (25.9, 50.0) 
        
  ≤ 40   (%) 65 (55) 65 (63) 
  > 40   (%) 53 (45) 38 (37) 
ER negative/positive (%)  66/52 (56/44) 60/43  (58/42) 
Pretreatment AMH (ng/ml)  Mean (sem) 1.10 (0.19) 1.47 (0.26) 
Planned chemotherapy      
Anthracycline regimens 
without taxane  (ACF)  
 N (%) 80 (68) 68 (66) 
Anthracycline regimens with 
taxane  (ACFT) 
N (%) 38 (32) 35 (34) 
Cumulative dose of 
cyclophosphamide, mg 
Median 
(range) 
5940 
(1400-6930) 
5940 
(2970-5940) 
    
 
Regimen abbreviations: A: anthracycline; C, cyclophosphamide; F, 5-fluorouracil ; T, 
taxane. 
 
Table 2. Primary outcome analysis, presented both as amenorrhoea only, and POI 
(amenorrhoea with elevated FSH). 
 
Outcome: Amenorrhoea between 12 and 24 months    
Age 
group 
Outcome 
Chemotherapy 
alone 
Chemotherapy 
plus Goserelin Total P 
Worst case 
imputation 
Best case 
imputation 
All No amenorrhoea 66 74 140    
   61.7% 77.9% 69%    
 Amenorrhoea 41 21 62    
  38.3% 22.1% 31%    
  TOTAL 107 95 202 0.015 0.017 0.024 
<= 40 No amenorrhoea 44 54 98    
  74.6% 90.0% 82%    
 Amenorrhoea 15 6 21    
   25.4% 10.0% 18%    
  TOTAL 59 60 119 0.032   
> 40 No amenorrhoea  22 20 42    
  45.8% 57.1% 51%    
 Amenorrhoea 26 15 41    
   54.2% 42.9% 49%    
  TOTAL 48 35 83 0.376   
        
Outcome: POI       
Age 
group 
Outcome 
Chemotherapy 
alone 
Chemotherapy 
plus Goserelin Total P   
All No POI 43 53 96    
   65.2% 81.5% 73.3%    
 POI 23 12 35    
  34.8% 18.5% 26.7%    
  TOTAL 66 65 131 0.048   
<= 40 No POI 24 38 62    
  80.0% 97.4% 89.9%    
 POI 6 1 7    
   20.0% 2.6% 10%    
  TOTAL 30 39 69 0.038   
> 40 No POI 19 15 34    
  52.8% 57.7% 54.8%    
 POI 17 11 28    
   47.2% 42.3% 45.2%    
  TOTAL 36 26 62 0.798   
 
 
Supplementary Table 1. Logistic regression analysis, exploring the effects of age, 
cyclophosphamide dose and pretreatment AMH on risk of amenorrhoea. 
 
 
Factor P OR Lower CI Upper CI 
Treatment 0.014 0.46 0.25 0.85 
Treatment 0.015 0.41 0.2 0.84 
Age <0.001 1.28 1.18 1.39 
Treatment 0.015 0.46 0.24 0.86 
Total cyclo dose (g) 0.070 1.15 0.99 1.34 
Treatment 0.148 0.49 0.19 1.29 
AMH 0.007 0.43 0.23 0.8 
Treatment 0.108 0.38 0.12 1.23 
Age <0.001 1.45 1.21 1.74 
Total cyclo dose (g) 0.27 1.16 0.89 1.52 
AMH 0.577 0.84 0.45 1.56 
 
 
